News and Events Archive

ADXBLADDER: A Novel Non-Invasive Aid for Bladder Cancer Monitoring

The innovative Arquer Diagnostic urine test for bladder cancer adds recurrence monitoring to the approved indications Sunderland, January 22nd 2019 ...
Read More

Arquer CEO Nadia Whittley Named Among Top 50 Female ‘Movers & Shakers’ in BioBusiness Report

Arquer Diagnostics Ltd (“Arquer”), a UK-based company focusing on the development of non-invasive cancer diagnostic tests today announced that CEO ...
Read More

Arquer Diagnostics Nominated For Two Upcoming Awards

With Spring approaching, Arquer Diagnostics are delighted to announce that we have been nominated for yet another healthcare business award ...
Read More

The Signs & Symptoms Of Prostate Cancer

ADXPROSTATE As you may already know, the most common cancer among men in the European Union is prostate cancer, with ...
Read More

ARQUER DIAGNOSTICS WINS AT BRIGHT IDEAS IN HEALTH AWARDS

Arquer Diagnostics are proud to announce that ADXBLADDER was chosen as the winner of the Outstanding Industry Collaboration with the ...
Read More
innovation

US Bladder Health Month

Many of us tend not to think about our bladder health, or how much this vital organ can affect our ...
Read More

Arquer Diagnostics Wins Outstanding Industry Collaboration at Bright Ideas in Health Awards

Newcastle, 17th November 2017: Arquer Diagnostics are proud to announce their status as Winners of the Outstanding Industry Collaboration with ...
Read More

Movember – Raising Money For Men’s Health

For almost 14 years, the Movember Foundation has been dedicated to raising money and spreading awareness of some of the ...
Read More

Arquer in the news

Click here to read an article that appeared on trendsinmenshealth.com recently ...
Read More

INNOVATION SHOWCASE: ARQUER DIAGNOSTICS

An interesting article about Arquer Diagnostics being selected to exhibit in the Innovation Showcase at this year's VentureFest North East ...
Read More

Bladder Cancer Survival and Recurrence

The chances of survival as a bladder cancer patient come down to the type of bladder cancer you have, the ...
Read More
bladder cancer

ADXBLADDER: An update on the launch of novel bladder cancer diagnostic test

ADXBLADDER Launch at SIU 2017 Arquer Diagnostics this month launched the ADXBLADDER cancer diagnostic test at the 37th Société Internationale ...
Read More

Non-invasive urine test provides game changer in bladder cancer

New Bladder Cancer diagnostic test provides a unique combination of high sensitivity and negative predictive value Lisbon, Portugal 21st October ...
Read More

Arquer Diagnostics Named As Finalists in “Bright Ideas In Health Awards” with ADXBLADDER

Arquer Diagnostics is delighted to announce our status as shortlisted finalists for the NHS’s Bright Ideas in Health Awards 2017 ...
Read More

The Signs & Symptoms Of Bladder Cancer

Bladder Cancer Statistics Bladder cancer is the 7th most common cancer here in the UK, with over 10,000 brits diagnosed ...
Read More

Paving The Way For ADXBLADDER

Arquer Diagnostics Each year in Europe, there are over 150,000 bladder cancer diagnoses, but up to a staggering 30% of ...
Read More

Arquer Diagnostics announces CE Mark for its breakthrough bladder cancer test ADXBLADDER

Arquer Diagnostics Ltd (“Arquer”), an in-vitro diagnostic company, developing breakthrough diagnostic tests for the detection of bladder and prostate cancer, ...
Read More

Arquer Diagnostics announces commercial partnership agreement for UK and Ireland

Arquer Diagnostics Ltd (“Arquer”), an in-vitro diagnostic company, developing breakthrough diagnostic tests for the detection of bladder and prostate cancer, ...
Read More

Arquer Diagnostics raises £2.1 million in series B funding led by Longwall Venture

Arquer Diagnostics Ltd (“Arquer”), an in-vitro diagnostic company, developing breakthrough diagnostic tests for the detection of bladder and prostate cancer, ...
Read More

Arquer Diagnostics completes patient recruitment for MCM5 clinical trial

801 patients recruited for international clinical study to evaluate Arquer’s ELISA-based urine test for bladder cancer Study results will serve ...
Read More

Arquer Diagnostics awarded funding under Innovate UK’s Biocatalyst programme

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer ...
Read More

Arquer Diagnostics Appoints Nadia Whittley as CEO

Sunderland, UK, 1st December 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ...
Read More

Arquer Diagnostics and the University of Sunderland collaborate to extend application of cancer diagnostic

Partnership will investigate non-invasive specimen preparation techniques for Arquer’s MCM5-ELISA test in a wider range of cancers Sunderland, UK, 17 ...
Read More

Arquer Diagnostics Appoints Louise Flintoft as Product Manager

Appointment strengthens senior team in preparation for EU regulatory approval and commercial launch of Mcm5-ELISA test Sunderland, UK, 13 July ...
Read More

Arquer Diagnostics signs Manufacturing and Supply Agreement with Euro Diagnostica

Sunderland, UK, 08 February 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ...
Read More

Arquer Diagnostics Receives Ethical Approval for Largest Privately Funded Bladder Cancer Study in UK

Arquer’s high sensitivity, ELISA test in study for Bladder Cancer Six month, multi-centre 800 patient clinical trial Study builds on ...
Read More

Arquer Diagnostics Announces Clinical Study for Recurrent Bladder Cancer

High Sensitivity, ELISA test in study for Bladder Cancer recurrence Six month, investigator-led study at Southampton University Study builds on ...
Read More

UroSens Announces Corporate Name Change and Rebranding to Arquer Diagnostics Ltd

Rebranding reflects Company’s expansion into new oncology areas Sunderland and Cambridge, UK, 20 July 2015: UroSens Ltd, a diagnostic company ...
Read More

UroSens Secures £2 Million Investment to commercialise Urine-Based Diagnostic Test for Bladder and Prostate Cancer

A cancer diagnostic company located in Sunderland and Cambridge which is developing a novel, non-invasive urine test for the detection ...
Read More

UroSens Receives £0.5 Million Funding and Enters into Clinical Trials for Bladder Cancer Diagnostic

Board of Directors Strengthened with Key Appointments. Cambridge and Sunderland, UK, 17 June 2013: UroSens Ltd, a start-up diagnostic company ...
Read More

Clinical trial approval granted

We are pleased to announce that ethical approval has been granted for a clinical trial to evaluate the Mcm5 immunoassay ...
Read More

Dr Sandy Primrose MBE appointed as non-Executive Chairman

Urosens is pleased to announce the appointment of Dr Sandy Primrose MBE, (Arrayjet, Lab901, Amersham International), as non-Executive Chairman. His ...
Read More

Urosens announce the CE marking of the Mcm5 ELISA kit

We are pleased to announce the CE marking of the Mcm5 ELISA kit.  This marks a significant step in the ...
Read More

Technology Strategy Board GRD Development grant

UroSens Ltd, a uro-oncology diagnostic company, based on the Babraham Research Campus, Cambridge, UK, is pleased to announce that they ...
Read More